BofA Downgrades Auxilium Pharmaceuticals (AUXL) to Neutral
More News related to AUXL
- Bank of America Resumes Coverage on Auxilium Pharmaceuticals (AUXL) with a Buy
- Auxilium Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- Auxilium Pharmaceuticals to Present at the Credit Suisse 18th Annual Global Healthcare Conference
- Auxilium Pharmaceuticals, Inc. (AUXL) Chief Executive Officer and President to Ring The NASDAQ Stock Market Closing Bell
- Auxilium Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference
More News related to Downgrades
- JANCO Partners Downgrades Energy Conversion Devices (ENER) to Sell
- Feltl & Co. Downgrades ArcSight (ARST) to Sell
- Credit Suisse Downgrades Comcast (CMCSA) to Neutral
- Citi Downgrades AK Steel (AKS) to Hold
- Citi Downgrades Netflix (NFLX) to Hold
Bank of America downgrades Auxilium Pharmaceuticals (Nasdaq: AUXL) from Buy to Neutral.
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing and marketing products to urologists, endocrinologists, orthopedists, and select primary care physicians primarily in the United States.
Related Categories
DowngradesStocks Mentioned
-0.10Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
